Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Haemophilia |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1111/j.1365-2516.2012.02920.x |
| Field | Oncology and hematology |
| Keywords | bleeding disorders; inhibitor |
| Description | Haemophilia registries, such as HemoRec, provide a valuable source of real-world data for the study of treatment modalities. We have reported that early treatment with rFVIIa appeared more effective than delayed-onset treatment in controlling the incidence of re-bleeding. The current study investigated whether time to treatment and/or initial dose of rFVIIa affects bleeding duration and, for the first time, their impact on acute pain control in inhibitor patients. |